{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:42:22Z","timestamp":1793313742918,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The main protease, M\n                    <jats:sup>pro<\/jats:sup>\n                    (or 3CL\n                    <jats:sup>pro<\/jats:sup>\n                    ) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide. Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor. Here, we show the prodrug and its parent GC373, are effective inhibitors of the M\n                    <jats:sup>pro<\/jats:sup>\n                    from both SARS-CoV and SARS-CoV-2 with IC\n                    <jats:sub>50<\/jats:sub>\n                    values in the nanomolar range. Crystal structures of SARS-CoV-2 M\n                    <jats:sup>pro<\/jats:sup>\n                    with these inhibitors have a covalent modification of the nucleophilic Cys145. NMR analysis reveals that inhibition proceeds via reversible formation of a hemithioacetal. GC373 and GC376 are potent inhibitors of SARS-CoV-2 replication in cell culture. They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals. The work here lays the framework for their use in human trials for the treatment of COVID-19.\n                  <\/jats:p>","DOI":"10.1038\/s41467-020-18096-2","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T06:04:31Z","timestamp":1598508271000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":411,"title":["Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3439-8788","authenticated-orcid":false,"given":"Wayne","family":"Vuong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4164-9573","authenticated-orcid":false,"given":"Muhammad Bashir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-010X","authenticated-orcid":false,"given":"Conrad","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Arutyunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1511-4540","authenticated-orcid":false,"given":"Tess","family":"Lamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4701-4576","authenticated-orcid":false,"given":"Justin","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly A.","family":"Saffran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-159X","authenticated-orcid":false,"given":"Ryan T.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9296-6069","authenticated-orcid":false,"given":"Marco J.","family":"van Belkum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-7299","authenticated-orcid":false,"given":"Michael A.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0983-7267","authenticated-orcid":false,"given":"D. Lorne","family":"Tyrrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2996-0326","authenticated-orcid":false,"given":"John C.","family":"Vederas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4745-9153","authenticated-orcid":false,"given":"M. Joanne","family":"Lemieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"18096_CR1","unstructured":"WHO. www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports (2020)."},{"key":"18096_CR2","unstructured":"WHO. http:\/\/www.who.int\/csr\/sars\/country\/2003_07_11\/en\/ (2003)."},{"key":"18096_CR3","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","volume":"59","author":"T Pillaiyar","year":"2016","unstructured":"Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y. & Jung, S. H. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3cl protease inhibitors: peptidomimetics and small molecule chemotherapy. J. Med Chem. 59, 6595\u20136628 (2016).","journal-title":"J. Med Chem."},{"key":"18096_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1021\/cr950025u","volume":"97","author":"HH Otto","year":"1997","unstructured":"Otto, H. H. & Schirmeister, T. Cysteine proteases and their inhibitors. Chem. Rev. 97, 133\u2013172 (1997).","journal-title":"Chem. Rev."},{"key":"18096_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nrd3053","volume":"9","author":"M Drag","year":"2010","unstructured":"Drag, M. & Salvesen, G. S. Emerging principles in protease-based drug discovery. Nat. Rev. Drug Discov. 9, 690\u2013701 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"18096_CR6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/nrd1907","volume":"4","author":"C Flexner","year":"2005","unstructured":"Flexner, C., Bate, G. & Kirkpatrick, P. Tipranavir. Nat. Rev. Drug Discov. 4, 955\u2013956 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"18096_CR7","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.1021\/bi00025a024","volume":"34","author":"BA Malcolm","year":"1995","unstructured":"Malcolm, B. A. et al. Peptide aldehyde inhibitors of hepatitis A virus 3C proteinase. Biochemistry 34, 8172\u20138179 (1995).","journal-title":"Biochemistry"},{"key":"18096_CR8","doi-asserted-by":"crossref","unstructured":"Chang, K. O., Kim, Y., Lovell, S., Rathnayake, A. D. & Groutas, W. C. Antiviral drug discovery: norovirus proteases and development of inhibitors. Viruses 11, 197 (2019).","DOI":"10.3390\/v11020197"},{"key":"18096_CR9","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.jmb.2007.06.001","volume":"371","author":"J Yin","year":"2007","unstructured":"Yin, J. et al. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase. J. Mol. Biol. 371, 1060\u20131074 (2007).","journal-title":"J. Mol. Biol."},{"key":"18096_CR10","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.1128\/JVI.03688-14","volume":"89","author":"Y Kim","year":"2015","unstructured":"Kim, Y. et al. Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses. J. Virol. 89, 4942\u20134950 (2015).","journal-title":"J. Virol."},{"key":"18096_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/1098612X17729626","volume":"20","author":"NC Pedersen","year":"2018","unstructured":"Pedersen, N. C. et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J. Feline Med. Surg. 20, 378\u2013392 (2018).","journal-title":"J. Feline Med. Surg."},{"key":"18096_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.antiviral.2018.10.015","volume":"160","author":"KD Perera","year":"2018","unstructured":"Perera, K. D. et al. Protease inhibitors broadly effective against feline, ferret and mink coronaviruses. Antivir. Res. 160, 79\u201386 (2018).","journal-title":"Antivir. Res."},{"key":"18096_CR13","doi-asserted-by":"publisher","first-page":"11754","DOI":"10.1128\/JVI.01348-12","volume":"86","author":"Y Kim","year":"2012","unstructured":"Kim, Y. et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. 86, 11754\u201311762 (2012).","journal-title":"J. Virol."},{"key":"18096_CR14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejmech.2018.03.004","volume":"150","author":"AC Galasiti Kankanamalage","year":"2018","unstructured":"Galasiti Kankanamalage, A. C. et al. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur. J. Med. Chem. 150, 334\u2013346 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"18096_CR15","doi-asserted-by":"crossref","unstructured":"Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 368, 409\u2013412 (2020).","DOI":"10.1126\/science.abb3405"},{"key":"18096_CR16","doi-asserted-by":"crossref","unstructured":"Jin, Z. et al. Structure of M(pro) from COVID-19 virus and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","DOI":"10.1038\/s41586-020-2223-y"},{"key":"18096_CR17","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.chembiol.2004.08.011","volume":"11","author":"JE Blanchard","year":"2004","unstructured":"Blanchard, J. E. et al. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem. Biol. 11, 1445\u20131453 (2004).","journal-title":"Chem. Biol."},{"key":"18096_CR18","doi-asserted-by":"crossref","unstructured":"Dai, W. et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331\u20131335 (2020).","DOI":"10.1126\/science.abb4489"},{"key":"18096_CR19","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1128\/JVI.02680-07","volume":"82","author":"J Shi","year":"2008","unstructured":"Shi, J., Sivaraman, J. & Song, J. Mechanism for controlling the dimer-monomer switch and coupling dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease. J. Virol. 82, 4620\u20134629 (2008).","journal-title":"J. Virol."},{"key":"18096_CR20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/pro.76","volume":"18","author":"N Zhong","year":"2009","unstructured":"Zhong, N. et al. C-terminal domain of SARS-CoV main protease can form a 3D domain-swapped dimer. Protein Sci. 18, 839\u2013844 (2009).","journal-title":"Protein Sci."},{"key":"18096_CR21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.virol.2009.03.034","volume":"388","author":"T Hu","year":"2009","unstructured":"Hu, T. et al. Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure. Virology 388, 324\u2013334 (2009).","journal-title":"Virology"},{"key":"18096_CR22","doi-asserted-by":"publisher","first-page":"e1005531","DOI":"10.1371\/journal.ppat.1005531","volume":"12","author":"Y Kim","year":"2016","unstructured":"Kim, Y. et al. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog. 12, e1005531 (2016).","journal-title":"PLoS Pathog."},{"key":"18096_CR23","doi-asserted-by":"crossref","unstructured":"Wang, C. et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J. Med. Virol. 92, 667\u2013674 (2020).","DOI":"10.1002\/jmv.25762"},{"key":"18096_CR24","doi-asserted-by":"crossref","unstructured":"Biswas, A., et al. Emergence of Novel Coronavirus and COVID-19: whether to stay or die out? Crit. Rev. Microbiol. 46, 182\u2013193 (2020).","DOI":"10.1080\/1040841X.2020.1739001"},{"key":"18096_CR25","doi-asserted-by":"crossref","unstructured":"Gordon, C. J. et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 295, 6785\u20136797 (2020).","DOI":"10.1074\/jbc.RA120.013679"},{"key":"18096_CR26","doi-asserted-by":"publisher","unstructured":"Grein, J. et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N. Engl. J. Med. 382, https:\/\/doi.org\/10.1056\/NEJMoa2007016 (2020).","DOI":"10.1056\/NEJMoa2007016"},{"key":"18096_CR27","doi-asserted-by":"crossref","unstructured":"Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883 (2020).","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"18096_CR28","doi-asserted-by":"publisher","first-page":"11886","DOI":"10.1128\/JVI.01528-14","volume":"88","author":"X Deng","year":"2014","unstructured":"Deng, X. et al. Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance. J. Virol. 88, 11886\u201311898 (2014).","journal-title":"J. Virol."},{"key":"18096_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","volume":"98","author":"L Menendez-Arias","year":"2013","unstructured":"Menendez-Arias, L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antivir. Res. 98, 93\u2013120 (2013).","journal-title":"Antivir. Res."},{"key":"18096_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1107\/S0021889807057822","volume":"41","author":"A Gonzalez","year":"2008","unstructured":"Gonzalez, A. et al. Web-Ice: integrated data collection and analysis for macromolecular crystallography. J. Appl. Crystallogr. 41, 176\u2013184 (2008).","journal-title":"J. Appl. Crystallogr."},{"key":"18096_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. Sect. D. Biol. Crystallogr. 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. Sect. D. Biol. Crystallogr."},{"key":"18096_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. Sect. D. Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. Sect. D. Struct. Biol."}],"updated-by":[{"DOI":"10.1038\/s41467-020-19339-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18096-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18096-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18096-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T07:03:46Z","timestamp":1696575826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18096-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["18096"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-18096-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.03.073080","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4282"}}